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abstract
PURPOSE Off-label use of vemurafenib (VMF) to treat BRAFV600E mutation–positive, refractory, childhood
Langerhans cell histiocytosis (LCH) was evaluated.
PATIENTS AND METHODS Fifty-four patients from 12 countries took VMF 20 mg/kg/d. They were classified
according to risk organ involvement: liver, spleen, and/or blood cytopenia. The main evaluation criteria were
adverse events (Common Terminology Criteria for Adverse Events [version 4.3]) and therapeutic responses
according to Disease Activity Score.
RESULTS LCH extent was distributed as follows: 44 with positive and 10 with negative risk organ involvement.
Median age at diagnosis was 0.9 years (range, 0.1 to 6.5 years). Median age at VMF initiation was 1.8 years
(range, 0.18 to 14 years), with a median follow-up of 22 months (range, 4.3 to 57 months), whereas median
treatment duration was 13.9 months (for 855 patient-months). At 8 weeks, 38 complete responses and 16
partial responses had been achieved, with the median Disease Activity Score decreasing from 7 at diagnosis to
0 (P , .001). Skin rash, the most frequent adverse event, affected 74% of patients. No secondary skin cancer
was observed. Therapeutic plasma VMF concentrations (range, 10 to 20 mg/L) seemed to be safe and effective.
VMF discontinuation for 30 patients led to 24 LCH reactivations. The blood BRAFV600E allele load, assessed as
circulating cell-free DNA, decreased after starting VMF but remained positive (median, 3.6% at diagnosis, and
1.6% during VMF treatment; P , .001) and was associated with a higher risk of reactivation at VMF dis-
continuation. None of the various empirical therapies (hematopoietic stem-cell transplantation, cladribine and
cytarabine, anti-MEK agent, vinblastine, etc) used for maintenance could eradicate the BRAFV600E clone.
CONCLUSION VMF seemed safe and effective in children with refractory BRAFV600E-positive LCH. Additional
studies are needed to find effective maintenance therapy approaches.
J Clin Oncol 37:2857-2865. © 2019 by American Society of Clinical Oncology
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INTRODUCTION
Langerhans cell histiocytosis (LCH) is a rare disease
characterized by inflammatory lesions that contain
abundant CD1a+CD207+ histiocytes.1,2 Its natural
course is heterogeneous and ranges from self-healing
lesions to multi-organ disease with life-threatening
consequences.3 LCH refractory to standard chemo-
therapy has a very poor prognosis,4 which can be im-
proved only by highly toxic second-line chemotherapy5
or hematopoietic stem-cell transplantation (HSCT).6
Patients with refractory LCH are usually younger than
2 years of age, have life-threatening involvement at
diagnosis, and frequently harbor the BRAFV600E muta-
tion.7 Vemurafenib (VMF), a BRAF (v-RAF murine
sarcoma viral oncogene homolog B) inhibitor originally
licensed for metastatic melanoma,8 was previously given
to two young children with refractory LCH.9,10 Faced with
critically ill children and the regulatory challenges of
organizing a phase I/II study in infants in a timely fashion,
individual physicians applied for permission to use VMF
off label. The European Medicines Agency approved
VMF as an orphan drug for this indication.11 Herein, we
report the results of an observational study of European
and Mediterranean VMF-treated children with LCH.
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PATIENTS AND METHODS
Patients
This study included 54 children treated for biopsy-proven,
BRAFV600E-mutated LCH considered refractory.12 Three
patients were reported previously,9,10,13 and their follow-up
was extended. Patients were classified as risk organ (RO)
positive (liver, spleen, and/or blood cytopenia12) or negative
according to LCH extent. Macrophage activation syndrome
was defined according to the literature.14 Patients with
sclerosing cholangitis (n = 4)15 or CNS neurodegeneration
(n = 7)16,17 were excluded from this analysis because they
usually have irreversible anatomic lesions. Patients with
RO-negative LCH had to have experienced at least two
treatment line failures, including at least one intensive
salvage regimen, on the basis of combinations of cla-
dribine, cytarabine, or clofarabine. Failure of first-line
therapy was characterized by disease progression in one
or more ROs after six or more vinblastine (VBL) doses (one
per week) and 28 days of prednisolone (minimum
dose, 40 mg/m2/d), with or without the adjunction of a third
drug. RO-positive patients were considered to have re-
fractory LCH when one or more ROs showed no im-
provement after first-line therapy. Failure could occur at
LCH onset or during its evolution in a patient whose initial
disease response was followed by reactivation in one or
more ROs.
Patients were included in their respective national LCH
registries (Commission Nationale d’Informatique et des
Liberte´s number in France 909027 and LCH-IV [Clinical-
Trials.gov identifier: NCT02205762] elsewhere),3 and
parents gave informed consent for enrollment in this ob-
servational study. In addition, after explaining to the parents
the use of an off-label medication in the absence of an
effective therapeutic alternative, informed consent was
obtained before prescribing VMF. This procedure is in
agreement with the Declaration of Helsinki.
VMF Dosing
Off-label VMF monotherapy was administered orally
(10 mg/kg twice a day) for at least 8 weeks.9 For children
younger than 2 years of age, the tablets (240mg each) were
split, crushed, and dissolved in water or milk for oral ad-
ministration.9 Dose and duration were adjusted while taking
into account tolerance, pharmacokinetics (PK), and
efficacy.
Criteria Used to Assess Outcome
Because LCH is a heterogeneous systemic disease, the
quantitative Disease Activity Score (DAS), which reflects
overall LCH extension, was used as an evolution criterion.18
The criteria applied in Histiocyte Society (HS) trials (non-
active disease [NAD] or active disease better [ADB], stable,
or worse)19,20 also were used. Finally, when present, tumors
were assessed with computed tomography scans and
Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.1.21 For RO-positive patients, complete response
(CR) was defined as a null DAS, which corresponds
to NAD in HS trials; the DAS declined for a partial re-
sponse (PR) but remained positive below 3, which corre-
sponds to ADB in HS trials. For RO-negative patients,
CR was the disappearance of the entire tumor burden,
whereas PR corresponded to a more than 50% tumor size
decrease.
LCH activity was assessed at VMF initiation, 2 weeks,
8 weeks, and 12 weeks, with reactivation defined as the
reappearance of disease activity after CR. Adverse events
(AEs) were graded according to the Common Terminology
Criteria for Adverse Events (version 4.3). VMF PK param-
eters (area under the curve, Cmin, Cmax, Tmax) were eval-
uated for 22 patients. For nine additional patients, only
steady-state residual concentrations were determined. The
assay used a previously published liquid chromatography-
tandem mass spectroscopy method.22 Blood BRAFV600E
load was assessed with various methods. Circulating cell-
free BRAFV600E DNA (ccf-BRAFV600E) quantification was
assessed for 34 patients using droplet-based digital poly-
merase chain reaction according to previously described
techniques10,23,24 and expressed as the percentage of
mutant alleles relative to the total number of alleles. The
positivity threshold for the detection of allele mutants with
this technique is 0.5 3 1023.23 For three other patients,
BRAFV600E was assessed by allele-specific real-time quan-
titative polymerase chain reaction on mononuclear cells for
two and whole-blood cells for one.25
Statistical Analyses
The first criterion evaluated was VMF safety according to
Common Terminology Criteria for Adverse Events (version
4.3), and the second was VMF efficacy according to the
overall response rate evaluated 8 weeks after starting
the drug. According to HS criteria, the overall response rate
was considered favorable when LCH activity was null (ie,
NAD) or decreased by more than 50% (ie, ADB).19,26
Between-group differences were compared using the
Mann-Whitney U test for quantitative variables and Fisher’s
exact test for qualitative variables. End points for survival
analyses were any type of reactivation and death. Survival
rates were estimated with the Kaplan-Meier method, and
subgroups were compared with the log-rank test. All par-
ticipating patients had to have started VMF before July 31,
2018. The cutoff date for this analysis was December
31, 2018.
RESULTS
Patient Characteristics
Fifty-four patients (28 males, 26 females) with multisystem
LCH from 12 countries were identified (Table 1; Data
Supplement): 44 patients were RO positive, including six
with macrophage activation syndrome, and 10 were RO
negative. Median age at LCH diagnosis was 0.9 years. VMF
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was started at a median age of 1.8 years; RO-positive
patients were younger (1.6 years) than RO-negative pa-
tients (3.4 years). The median initial diagnosis-to-VMF
initiation time was 0.7 years. Median VMF onset-to-last
examination follow-up was 22.1 months for a cumulative
follow-up of 1,232 months. Thirty-one patients were VMF
treated at the time of first LCH episode, and 23 patients
were VMF treated during reactivation. At VMF initiation, all
patients were considered active disease worse (n = 53) or
active disease stable (n = 1) according the HS criteria.19,20
Median DAS for all 54 children was 7 (range, 1 to 22).
Induction therapy consisted of VBL plus corticosteroids
(VBL + CS) for all patients (one cycle for 29 patients, two for
18 patients, and three or more for seven patients). In
addition, LCH refractoriness was distributed as follows:
cladribine monotherapy (five RO-negative patients and
seven RO-positive patients), cladribine and cytarabine
combination (eight RO-positive patients), clofarabine (two
RO-positive patients), and vincristine and cytarabine (three
RO-positive patients and five RO-negative patients).
TABLE 1. Characteristics of 54 VMF-Treated Patients With Childhood LCH in the International Series
Characteristic
All Patients,
No. (%)
RO Positive,
No. (%)
RO Negative,
No. (%) P*
No. of patients 54 44 10
Sex NS
Female 26 21 5
Male 28 23 5
Median age at diagnosis, years (range) 0.9 (0.1-6.5) 0.9 1.4 NS
First-line therapy
Vinblastine plus corticosteroids All All All
Cladribine monotherapy 12 (22.2) 7 (16) 5 (50)
Cladribine and cytarabine 8 (14.5) 8 (18) 0
Clofarabine 2 (3.7) 2 (4.5) 0
Vincristine and cytarabine 8 (16.7) 3 (7) 5 (50)
LCH status at VMF start 53 (98.1) ADW 43 ADW 10 ADW
According to HS status 1 (1.8) ADS 1 ADS
Median age at VMF start, years (range) 1.8 (0.18-14) 1.64 3.4 , .001
Hematologic dysfunction 41 (74.1) 41 (93) 0
Macrophage activation 6 (11.1) 6 (14) 0
Median DAS 7 10 3 , .001
VMF dose at steady state, mg/kg 23.5 24 20 NS
Total duration at last update, patient-months NS
Median 13.9 14.1 12.6
Total 855 698 157
Median DAS 60-80 days after VMF start 0 0 0
Response according to HS criteria at week 8
NAD 38 (70.3) 32 (72.1) 6 (63.6)
ADB 16 (39.6) 12 (27.9) 4 (36.4)
Toxicity 40 (74.1) 32 (72) 8 (80)
Skin rash 37 (68.5) 29 (65) 8 (80)
Extra skin 8 (14.8) 7 (15) 1 (10)
Follow-up since VMF start, patient-months NS
Median 22.5 21.7 25
Range 2.7-57 4.3-42 2.7-57
Total 1,234 988 245
Abbreviations: ADB, active disease better; ADS, active disease stable; ADW, active disease worse; DAS, Disease Activity Score; HS, Histiocyte
Society; LCH, Langerhans cell histiocytosis; NAD, nonactive disease; NS, not significant; RO, risk organ; VMF, vemurafenib.
*RO negative v RO positive.
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Therapeutic Intervention
Median VMF administration duration from onset to dis-
continuation for the 30 assessable patients was 6.1 months
(range, 2 to 14.7 months). For the 24 remaining patients,
VMF cessation could not be evaluated because the patients
switched immediately at discontinuation to HSCT (n = 2),
cladribine and cytarabine (n = 1), or VBL + CS (n = 2) or
were still taking VMF at the last visit (n = 19). With con-
sideration of all patients, including those for whom VMFwas
secondarily resumed, the median total VMF administration
duration was 13.9 months (range, 2 to 38 months), with
cumulative duration lasting 855 patient-months (Table 1;
Data Supplement). The latter can be broken down as
follows: 225 months for the initial administration until first
stoppage, 303 months for the 30 patients who stopped
VMF at least once after resuming VMF, 83 months for
patients who switched to HSCT and chemotherapy, and
244 months for those still taking VMF at the last follow-up.
VMF PK Parameters
The residual VMF level measured at least 14 days after
starting the drug (steady state) seemed to coincide with
toxicity and efficacy. The 95% CI for the plasma VMF
concentration was 11.6 to 20.6 mg/L for a median dose of
21 mg/kg/d (range, 13 to 41 mg/kg/d; mean, 23 mg/kg/d),
and seems to be VMF’s therapeutic range for pediatric
patients with LCH (Simon et al, manuscript in preparation).
The dose was modified for 12 patients because of mild skin
AEs (three reduced doses), physician choice (three in-
creased doses), PK analysis (three increased doses), or
reactivation 3 months after VMF onset (three increased
doses). Three patients’ PRs were associated with in-
sufficient plasma VMF concentrations less than 10 mg/L;
when their doses were doubled, those concentrations
reached the therapeutic range, which led to clinical CR.
AEs
Fifty-four AEs occurred in 40 patients (Data Supplement).
AEs were predominantly dermatologic (37 of 40; 92%), with
only eight nondermatologic. Most AEs (33 of 40; 82%) were
grade 1 or 2 and transient or had no permanent sequelae:
The 37 dermatologic AEs were skin rashes for all 37 pa-
tients, with exacerbated skin photosensitivity in 13 or
panniculitis in seven. Two had transiently abnormal nails in
addition to skin rashes. The eight nondermatologic AEs
were two transient grade 1 QT-interval prolongations at
higher doses; grade 1 transient joint pain for two and grade
2 for a third; and one each of transient mild liver cytolysis,
grade 3 transient clonus of the neck and limbs, and grade 3
tumor necrosis–related nose bleeds. Finally, VMF patient
#3000068 died as a result of sepsis and pancytopenia
associated with concomitant clofarabine use (Data
Supplement).
AEs seemed to be more frequent when residual (after
24 hours) plasma VMF concentrations were high. For ex-
ample, grade 1 QT-interval prolongations occurred with
plasma VMF at 37 and 72 mg/L, and the three patients with
grade 3 panniculitis had levels of 40 to 74mg/L (#1509554,
42.9 mg/L; #1506637, 40.2 mg/L; #1509564, 74.1 mg/L).
For all patients with grade 3 toxicity, lowering of the VMF
dose led to AE regression or disappearance. No secondary
malignancy or other blood or immune toxicity was ob-
served. Even though follow-up was short, no growth delay
was noted, but several patients developed commu-
nity infections, like chicken pox or influenza, without
complications.
Therapeutic Responses
At 8 weeks, 38 patients had CRs (NAD) and 16 PRs (ADB;
Fig 1A). The median DAS decreased from 7 at VMF initi-
ation to 0 on day 60 (P , .001; Fig 1B), and that decline
was more remarkable (10 to 0) for RO-positive than for RO-
negative patients (3 v 0; Fig 1A). The 16 patients with
persistent PR had minimal clinically active disease with
mild spleen enlargement (n = 6), mild liver enlargement
(n = 3), or skin lesions (n = 7). Of note, responses appeared
rapidly (Fig 1C). Two patients’ soft tissue tumor masses
became necrotic, and one developed severe epistaxis as
a result of pharyngeal lesion necrosis on day 60. In addition,
responses were assessed with computed tomography scan
(RECIST version 1.1),21 with planar evaluation for 11 as-
sessable patients with multisystem LCH. Tumors in RO-
negative patients showed a more than 70% decrease
compared with pre-VMF, and those patients benefited from
bone remodeling (Fig 1D).
VMF Discontinuation, Reactivation, Long-Term
Outcomes, and Maintenance
The response to VMF persisted as long as the patient
remained on treatment, with three requiring dose adap-
tation. VMF was stopped after a median of 6.1 months
(range, 2 to 14.7 months) for 30 patients without any
maintenance therapy. Twenty-four of those patients rapidly
experienced reactivations (median, 0.9 months; range, 0.1
to 7.3 months) after discontinuation (Data Supplement).
The 6- and 12-month reactivation rates were 72% (95% CI,
56% to 88%) and 84% (95% CI, 68% to 95%), respectively
(Fig 2A). RO status determined the reactivation pattern.
Among the 30 patients who stopped VMF, 22 were RO-
positive patients who developed 20 reactivations (RO-positive
reactivations for 18 patients), whereas four reactivations
among the eight RO-negative patients were RO negative
(three with skin rash, one with pituitary, and/or three with
bone). The reactivation rate was higher for RO-positive
patients than for RO-negative patients (Fig 2B) and for
patients positive, but not negative, for ccf-BRAFV600E
(Fig 2C). The 12-month reactivation rate was 95% for RO-
positive patients v 57% for RO-negative patients (P , .001)
and 100% for patients positive for ccf-BRAFV600E v 33% for
those negative for ccf-BRAFV600E on VMF (P = .006).
Among the 20 RO-positive reactivations, 18 were treated
effectively by reintroducing VMF; the patient given VMF and
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clofarabine experienced major toxicity (death), and the
patient with only skin-localized involvement was left un-
treated (Data Supplement). The four RO-negative reac-
tivations were treated with VMF in two patients; one patient
was given VBL, and the other was left untreated. Later,
among the 18 VMF-treated RO-positive reactivations, two
patients underwent HSCT, one after unsuccessful VBL +
CS reintroduction; two were prescribed VMF and cobi-
metinib; and one received VBL + CS alone. Those main-
tenance strategies failed to control LCH because the
disease always reactivated when VMF was withdrawn.
If we add the five patients who had received chemotherapy
before any reactivation after VMF stoppage to the six given
chemotherapy after post-VMF reactivation, four mainte-
nance regimens could be evaluated. The findings were
disappointing because two of the three patients who un-
derwent HSCT, two of three who received cladribine and
cytarabine, and four of the five treated with VBL + CS had
reactivations, and clofarabine adjunction was complicated
by lethal sepsis. In addition, two patients treated with VMF
and cobimetinib experienced reactivations when that
combination was stopped. The 2-year overall survival rate
was 98% (95% CI, 88% to 100%; Fig 2D).
ccf-BRAFV600E Load as a Surrogate End Point
Thirty-seven patients’ plasma ccf-BRAFV600E loads were
evaluated at various times. It was assessed in two
patients’ whole-blood mononuclear cells, in one patient’s
whole-blood cells, and in DNA extracted from plasma for
the others. Although the results of the three methods seem
to be comparable, only the ccf-BRAFV600E results of
34 patients were analyzed but not all at the same time.
At diagnosis, a ccf-BRAFV600E load, expressed as the per-
centage of mutant alleles relative to the total number
of alleles, was evaluated for 27 patients and detectable
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FIG 1. Langerhans cell histiocytosis (LCH) evolution on vemurafenib (VMF) according to various criteria. (A) Waterfall figure of the Disease Activity Score
(DAS) change between day 1 and week 8 after starting VMF. (B) DAS evolution between VMF day 1 and week 8 according to the LCH extent of risk organ
(RO) involvement (RO positive, RO negative). The differences were significant for the two groups (P, .001), but the amplitude was muchmore pronounced
for the RO-positive group. (C) Female patient #1509231 with massive cervical lymph nodes viewed from the back on day –1 (DAS = 3; left) and after their
disappearance on day 14 (right) of VMF administration. Her multisystemic RO-positive LCH was initially treated with two cycles of vinblastine plus
corticosteroids (VBL + CS) that obtained good responses before reactivation, which was then retreated unsuccessfully with VBL + CS and then cladribine
before further worsening. (D) Imaging of left-side temporal bone lesion in male patient #1509707. After an initial good response to standard VBL + CS
induction, his initially RO-positive LCH reactivated locally on the first maintenance regimen. VBL + CS was prescribed again, but disease progression led to
left-sided facial palsy. The first computed tomography scan (left) shows left-side temporal bone destruction and soft tissue involvement, whereas the
computed tomography scan at week 6 on VMF (right) shows that almost all the initial lesions had disappeared and bone was partially remodeled.
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above the 0.53 1023 threshold for 18 of the 21 RO-positive
patients and one of the six RO-negative patients. Twenty-
two patients (four RO negative, 18 RO positive) had plasma
samples available for longitudinal follow-up; their ccf-
BRAFV600E loads were tested in the same laboratory (Fig 3),
as reported previously.23 ccf-BRAFV600E was detected in the
22 patients at VMF initiation, with a median load of 3.1%
(range, 0.31% to 22%). At 8 weeks, the ccf-BRAFV600E load
(median, 0.7%; range, 0.001% to 18%) remained within
the same range as on day 15 (when tested) with no further
decrease, despite good clinical responses. When the ccf-
BRAFV600E load was evaluated more than 6 months after
starting VMF, it remained positive for nine of 12 patients
(median, 1.6%; range, 0.001% to 26%). Moreover, all
patients positive for ccf-BRAFV600E 2 or more months post-
VMF initiation experienced relapse soon after that agent’s
discontinuation (Fig 2C). Even HSCT failed to clear the
BRAFV600E clones, whose loads were still high 6 months
after HSCT for two assessable patients.
DISCUSSION
We report the first, to our knowledge, international series of
children with refractory LCH treated with the BRAF inhibitor
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FIG 2. Kaplan-Meier plots of Langerhans cell histiocytosis (LCH) reactivation and survival rates. (A) Thirty assessable patients after vemurafenib (VMF)
withdrawal with 95% CIs. (B) According to initial LCH risk organ (RO) involvement (RO positive, RO negative). The probability of reactivation was
significantly higher for patients with RO-positive LCH (P = .0041). (C) According to circulating cell-free BRAFV600E loads in plasma of 13 assessable
patients after stopping VMF as determined by polymerase chain reaction. Despite the small number of available values, the probability of reactivation
was significantly higher when the cell-freeBRAFV600E load was positive (P, .001) on VMF (P = .0124). (D) Survival rate with 95%CI since VMF onset for
the 54 children with LCH.
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VMF. According to literature criteria,4,12,27 these patients
had severe, life-threatening LCH manifestations because
they all failed to respond to conventional therapies. Vali-
dated therapeutic options are currently cladribine and
cytarabine chemotherapy5 or HSCT,6 which may reverse
such situations, with 15% to 25% mortality and long hos-
pitalization. No therapeutic trial was available for this group of
infants with severely compromised organ function and at high
risk of death. In the face of this difficult situation, our results
show that VMF induced rapid and dramatic clinical im-
provement with only mild or transient toxicity. Indeed, VMF
seemed to be far less toxic than cladribine and cytarabine or
HSCT, which thereby allowed treatment of patients in low-
income areas without access to specialized hematologic
intensive care or HSCT facilities (Gaza Strip, Algeria, and
Tunisia). This outcome is similar to that obtained for a US
series of 21 patients, eight of whom with LCH that could be
classified as refractory according the literature, even though
highly heterogeneous treatments had been used (various
BRAF or mitogen-activated extracellular signal–regulated
kinase [MEK] inhibitors). Moreover, two of the eight patients
had LCH associated with juvenile xanthogranuloma.28
VMF toxicity in children also contrasts favorably with adults
treated for melanoma. Despite the small size of our series
and in light of the very high risk of secondary skin tumors
observed in adults with melanoma (approximately 30%),29,30
the absence of any secondary tumors in 54 patients after
855 patient-months on VMF can be considered reassuring.
The frequentmild skin AEs (eg, photosensitivity, panniculitis)
cannot be underestimated, but patients remain susceptible
to these with dose adjustment.
The absence of a pediatric VMF formulation was also
a concern; it was necessary to crush tablets and use
a weight-based dose adaptation. However, our PK data
demonstrate the effectiveness of that approach. In addition
to the good safety profile and good bioavailability of VMF, our
results show that active, refractory LCH responds rapidly to
the drug. The clinical response rate was higher and faster
than the best observed with any previous therapies, in-
cluding cladribine and cytarabine.5 Moreover, the few PRs
seemed to reflect a lack of drug bioavailability and could
be corrected by dose adjustment with therapeutic drug
monitoring.
Our findings show that despite its good clinical efficacy,
VMF was unable to eradicate the neoplastic clone. The
majority of patients who discontinued VMF experienced
LCH reactivations. Various strategies have been proposed
to eradicate the underlying LCH clone, but none have been
satisfactory. Among the three patients who underwent
HSCT to eradicate LCH, two rapidly experienced reac-
tivation, and follow-up was too short for the third. Above all,
the blood BRAFV600E load was never negative after HSCT.31
As maintenance therapy, two patients received a BRAF
inhibitor and MEK inhibitor combination; their blood
BRAFV600E loads never changed durably. How to eradicate
the BRAFV600E clone remains elusive.
The last important study-derived information was the
usefulness of evaluation as a surrogate marker of LCH
activity. ccf-BRAFV600E was shown previously to correlate
with disease activity.23 Indeed, we observed that almost all
VMF-treated patients, despite being considered clinical
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responders, maintained detectable BRAFV600E levels and
that circulating alleles were associated with a higher
reactivation risk at VMF discontinuation. Despite the
seeming global efficacy of VMF, the most important limi-
tation of this study is its observational design. The design
respected some key criteria with regard to patient selection
and the choice of pertinent end points for these patients
with life-threatening LCH. Indeed, we are at the dawn of the
development of anti-BRAF therapy for LCH.
In conclusion, VMF is at least a bridging option for patients
with life-threatening, multisystem LCH. Prospective clinical
trials are needed urgently to determine the appropriate
treatment duration and add-on treatment options for clone
eradication and LCH cure.
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